We investigated the effect of free, non-transferrin-bound iron occurring in haematological stem cell transplant patients on growth of Staphylococcus epidermidis in serum in vitro, and prevention of bacterial growth by exogenous apotransferrin. S. epidermidis did not grow in normal serum at inoculated bacterial densities up to 10 3 cfu ml 31 but slow growth could be detected at higher initial inocula. Addition of free iron abolished the growth-inhibitory effect of serum, whereas addition of apotransferrin again restored it. Appearance of free iron and loss of growth inhibition coincided in patient serum samples taken daily during myeloablative therapy. Intravenously administered apotransferrin effectively bound free iron and restored the growth inhibition in patient sera. The results suggest that exogenous apotransferrin might protect stem cell transplant patients against infections by S. epidermidis and possibly other opportunistic pathogens.
Introduction
Infections cause signi¢cant morbidity and mortality in haematological patients receiving myeloablative conditioning therapy and allogeneic stem cell transplantation [1, 2] . Staphylococcus epidermidis is a major causative agent of bacteraemia and septic infections in neutropenic patients receiving intensive immunosuppressive therapy [3, 4] .
During chemotherapy-related neutropenia, plasmabased resistance factors against bacterial infections may become critical. One of the factors known to in£uence microbial growth is iron accessibility [5] . In normal conditions, plasma iron is tightly bound to the high-a⁄nity iron carrier protein transferrin, and the level of redox-active, non-transferrin-bound iron (NTBI) in plasma is very low. This is considered to prevent the growth of opportunistic pathogens, which do not possess e⁄cient molecular mechanisms to utilise transferrin-bound iron [6] . On the other hand, several studies have indicated that highdose chemotherapy of haematological malignancies is associated with an increase in serum total iron content, which often exceeds the iron binding capacity of transferrin and results in the appearance of NTBI in the serum of the patients [7^10] . Complete transferrin saturation and presence of NTBI are particularly common during myeloablative therapy and stem cell transplantation [11^13] .
There is both experimental and clinical evidence suggesting that hyperferraemia predisposes patients to infections with opportunistic pathogens. In experimental animal infections, the virulence of several organisms was markedly enhanced by iron administration to the host [14] . Several studies have found an association between fungal infections and a high transferrin saturation level in neutropenic leukaemia patients [15^18] . It has also been suggested that high transferrin saturation contributes to lethality of pneumococcal pneumonia [19] . However, it is not known whether high transferrin saturation as such, or the presence of NTBI, promotes microbial virulence.
In the present study we investigated the in£uence of transferrin saturation and NTBI on the growth of S. epidermidis in serum. The role of iron uptake mechanisms of S. epidermidis in the serum milieu has been unclear. Early studies indicated that in contrast to Staphylococcus aureus, coagulase-negative staphylococci were not able to grow in normal serum without iron supplementation [20] . On the other hand, it has been demonstrated that both S. epidermidis cells and the siderophore staphyloferrin A can displace iron from transferrin under in vitro conditions [21] . In our earlier study in serum-free conditions, S. epidermidis was not able to utilise transferrin-bound iron for growth unless high bacterial densities were present [22] . In the present study we found that S. epidermidis was not able to grow in serum unless either NTBI or a high initial count of bacteria was present. Further, we demonstrated that it is possible to prevent both the appearance of NTBI and growth of S. epidermidis in the serum of stem cell transplant patients by giving repeated infusions of exogenous apotransferrin.
Materials and methods

Patients
Twenty-six patients with haematological malignancies receiving allogeneic stem cell transplantation after myeloablative conditioning with cyclophosphamide and total body irradiation were enrolled in clinical trials with di¡er-ent doses of an investigational human plasma apotransferrin product (Apotransferrin SPR, Finnish Red Cross Blood Transfusion Service) [23] . Six patients received a single intravenous dose of 100 mg kg 31 of apotransferrin on day 3 after the stem cell transplantation [24] . Twenty patients were given repeated doses daily or every second day starting 6 days before the stem cell transplantation and continuing for 14^18 days. The total dose per patient varied between 0.3 and 0.6 g kg 31 in a low-dose group of 12 patients and was 1 g kg 31 in a high-dose group of eight patients. Ten patients were from a previous follow-up study and did not receive apotransferrin [13] . Prophylactic antibacterial agents routinely given to the patients were sulfamethoxazole/trimethoprim or cipro£oxacin. The clinical trials were approved by the ethical committee of the Helsinki University Central Hospital. Informed written consent of the patients was obtained.
Bacterial strains and culture conditions
Two multi-resistant clinical isolates of S. epidermidis (16779 and 19435) from neutropenic patients, which were resistant to methicillin and at least two antibiotic classes other than L-lactams, and the ATCC 12228 strain were used. Siderophore production was induced by precultivation in iron-depleted RPMI 1640 medium as previously described [22] . The bacteria were harvested in the late exponential growth phase and 10-fold dilutions were prepared in physiological saline.
An inoculum of 50 Wl was added to 200 Wl of serum bu¡ered with 50 mM HEPES bu¡er, pH 7.4, in microwells. The growth was monitored by optical density (OD) for 24 h at 37 ‡C with periodic shaking (Bioscreen C Microbiology Reader, Labsystems, Finland) in an airtight chamber maintained in a 5% CO 2 atmosphere. Serum pH was maintained at 7.3^7.4 and bicarbonate level at about 17 mM throughout the culture period. The detection limit for the increase in OD in 24 h (vOD) was 0.05 and the threshold density of S. epidermidis which could be detected was about 10 6 cfu ml 31 . Viable counts were determined by plating on trypticase-soy agar plates (bioMe ¤rieux, France). Sera with in vitro additions of ferric nitrilotriacetic acid prepared as described in [22] or apotransferrin were preincubated for 30 min at 37 ‡C in 3% CO 2 to ensure binding of iron to transferrin.
Transferrin, iron and other serum assays
Serum transferrin (reference range 1.75^3.13 g l 31 ) and C-reactive protein (CRP) (reference range 6 10 mg l 31 ) were measured by immunoturbidimetric methods. Serum total iron was measured by a colorimetric ferene-S method (reference range 8^30 WM for females and 10^31 WM for males). All above-mentioned measurements were done at the HUCH Laboratory Diagnostics of the Helsinki University Central Hospital. Transferrin saturation (%) was calculated by the formula : serum iron (WM)/serum transferrin (g l 31 )U3.98. NTBI was measured using the bleomycin-detectable iron assay adopted for small (25 Wl) serum volumes [25] . Brie£y, bleomycin was added to serum in the presence of ascorbic acid. Redox-active iron bound to bleomycin caused degradation of DNA in the mixture and the DNA degradation products were measured in microwell plates by a colorimetric thiobarbituric acid assay. A standard curve with 0.1^3 WM pure iron in water was calculated by linear regression of logarithmic values. The assay had a detection limit of 0.1 WM. The pH and bicarbonate concentrations in serum were measured using a blood gas analyser (ABL700, Radiometer).
Results
In£uence of NTBI on the growth of S. epidermidis in serum
No growth of S. epidermidis took place in normal serum samples inoculated with 10 3 cfu ml 31 of the bacteria, whereas the bacteria proliferated rapidly in serum supplemented with iron (Fig. 1A) . The three studied strains dis-played similar iron dependence in their growth. Normal serum samples had transferrin saturation of 24^30% and NTBI 6 0.1 WM. The amount of iron added to serum (45 WM) was su⁄cient to fully saturate transferrin and form NTBI in a concentration of 3.2 þ 0.8 WM (mean þ S.D., n = 5). When both apotransferrin (2 g l 31 ) and iron were added to the serum, no growth of the bacteria was observed (data not shown).
The in£uence of NTBI on bacterial growth in patient serum was studied with the two multiple drug-resistant S. epidermidis strains. Both strains grew rapidly in the serum samples of the three patients studied, which all contained fully saturated transferrin and NTBI (0.3 þ 0.1 WM). The addition of 0.1 g l 31 apotransferrin, which bound the NTBI, fully prevented the growth of the staphylococci, whereas the addition of iron-saturated holotransferrin had no e¡ect. The growth curves from one patient with and without transferrin additions are shown in Fig. 1B .
The in£uence of initial bacterial density on iron dependence of bacterial growth was studied in normal serum with and without iron addition. In iron-supplemented serum, inoculations in the range of 10 2^1 0 5 cfu ml 31 resulted in clearly detectable growth curves by OD monitoring, whereas without iron addition only the highest inoculum resulted in detectable growth ( Fig. 2A) . Determination of viable counts after 24 h indicated growth to 10 6 cfu ml 31 with starting densities of 10 4^1 0 5 cfu ml 31 and no detectable growth with 10 2^1 0 3 cfu ml 31 . After iron addition the growth consistently reached high concentrations (10 7^1 0 8 cfu ml 31 ) with all inoculations (Fig. 2B ).
In£uence of apotransferrin administration on bacterial growth in patient serum
A bacterial inoculum of 10 3 cfu ml 31 was used in the microwell system with vOD measurement, which allowed identi¢cation of samples with growth to at least 10 6 cfu Viable counts at the beginning and after 24 h in the same sera. Growth of strain 16779 was monitored as described in Fig. 1 . Bars indicate the mean and S.E.M. of repeated (n = 4) experiments. The di¡erence between the viable counts after 24 h in normal serum and in the same serum with NTBI was statistically signi¢cant at all starting cell densities (10 3 cfu ml 31 P 6 0.0001, 10 4 cfu ml 31 P 6 0.01 and 10 5 cfu ml 31 P 6 0.05, Student's t-test). ml 31 s 80% (Fig. 3) . Growth was detected in 87% (54/62) of the samples with NTBI, whereas only 4% (3/70) of the samples without NTBI grew (P 6 0.0001, Fisher' s 80%. Of the eight NTBI-positive samples not supporting growth, two were from a patient who had received vancomycin and four from a patient who was treated with a combination of tobramycin and ceftazidime.
In the ¢rst clinical trial in which a single intravenous dose of apotransferrin was given to the patients, serum samples from all six patients were positive for NTBI before apotransferrin administration and the inoculated bacteria grew in all of them (Fig. 4) . Immediately after the administration, the growth was prevented concurrently with a drop in transferrin saturation and disappearance of NTBI. The length of this bacteriostatic e¡ect of the single apotransferrin dose varied from 12 h to several days. The bacteriostatic e¡ect typically disappeared simultaneously with the reappearance of NTBI in serum (Fig.  4) . In the serum of a patient who received vancomycin on days 8^11, no growth of the staphylococci took place in spite of high transferrin saturation and NTBI on days 101 1 (Fig. 4B) .
In subsequent trials, apotransferrin was administered as repeated doses starting 6 days before the stem cell transplantation on the same day as the conditioning therapy. For comparison, growth was monitored in two patients who did not receive apotransferrin (Fig. 5A) . A sharp rise in serum iron content and appearance of NTBI occurred after the start of the conditioning and concomitantly, growth of inoculated staphylococci was detected. The lower apotransferrin doses tested were not su⁄cient to prevent the appearance of NTBI. The transferrin saturation remained at a high level, and bacteria grew in the serum samples which were positive for NTBI (Fig. 5B) . Repeated higher doses prevented the appearance of NTBI in ¢ve of the eight patients studied. No signi¢cant bacterial growth could be detected in the serum of a patient with no detectable NTBI during the whole study period (Fig. 5C ).
Infection markers in the patients receiving apotransferrin
To gain insight into whether NTBI is a risk factor for septic infections, markers for septic infections (fever s 38 ‡ s 30 mg l 31 ) were compared between the 10 patients who did not receive apotransferrin, 12 patients who re- Fig. 3 . Relation of bacterial growth measured as an increase in optical density (vOD) to transferrin saturation in the serum samples of the stem cell transplantation patients (n = 132). The growth of an inoculum of 10 3 cfu ml 31 of strain 16779 was monitored as the increase in optical density during 24 h. The line indicates the detection limit. Fig. 4 . E¡ect of a single intravenous administration of apotransferrin on transferrin saturation, NTBI and growth of S. epidermidis in the serum samples of three stem cell transplantation patients. Bacterial growth was measured as in Fig. 3 . The arrow indicates the intravenous injection of 100 mg kg 31 apotransferrin 3 days after the stem cell transplantation.
ceived repeated lower doses of apotransferrin and eight patients who received repeated higher doses. Positive blood cultures were obtained only from a minority of patients with suspected septic infections, which probably was due to the use of prophylactic antibiotics and rapid onset of treatment with intravenous antibiotics when signs of septic infections were detected.
Most patients were positive for the infection markers at least on one occasion during the stem cell transplantation period. When the total number of days with positive infection markers was evaluated as a proportion of all study days, there was a signi¢cant reduction in the number of days with fever and days with elevated CRP in the patient groups who received low and high doses of apotransferrin, respectively (Table 1) . When both markers were evaluated together, there was a signi¢cant reduction in the high-dose group (P 6 0.01). The number of days with intravenous antibacterial treatment was signi¢cantly lower in both patient groups receiving apotransferrin than in the control group. There was also a trend towards a lower proportion of days with antifungal therapy in the higher-dose group but this was not statistically signi¢cant.
Discussion
The results of the present study show that at initial densities up to 10 3 cfu ml 31 , S. epidermidis was able to grow in serum only when the transferrin was fully saturated and NTBI was present. This was shown both by adding iron to normal serum and by studying serum samples of patients undergoing stem cell transplantation, in which transferrin became fully saturated and NTBI appeared after the initiation of the myeloablative therapy. Further, the growth of S. epidermidis in serum was e¡ec-tively prevented when apotransferrin was added to the serum in vitro or when apotransferrin was intravenously administered to the patients to bind NTBI in circulation.
The results are in agreement with earlier ¢ndings [20] , indicating that in contrast to S. aureus, coagulase-negative staphylococci could not grow in serum without iron supplementation. We conducted the bacterial culturing under conditions which kept serum bicarbonate and pH at physiological levels, both of which in£uence transferrin iron binding [26] . We found 80% to be a threshold for transferrin saturation, above which bacterial growth took place in patient samples. In a previous study, this was also identi¢ed as the critical saturation level, above which redoxactive NTBI occurred in patients' sera [25] . In accordance, we observed a strong association between bacterial growth and NTBI in the patient serum samples.
The ability of S. epidermidis to multiply in serum in the absence of NTBI was dependent on the initial bacterial density. The bacteria grew in normal serum only at high initial densities (10 4^1 0 5 cfu ml 31 ) and the growth was much slower than in the presence of NTBI. This is in line with our earlier ¢ndings in serum-free conditions showing that in the presence of puri¢ed transferrin the growth of S. epidermidis was critically dependent on full transferrin saturation and the presence of NTBI [22] s 10 5 cfu ml 31 ). It has previously been demonstrated that S. epidermidis cells at high densities (10 8 cfu ml 31 ) could displace iron from transferrin [21] . This was attributed to a cell wall transferrin binding protein, identi¢ed as glyceraldehyde-3-phosphate dehydrogenase. However, a more recent study on iron acquisition mechanisms of S. aureus showed that this glycolytic enzyme has no a⁄nity for transferrin and another cell wall protein with iron-regulated expression was identi¢ed as a transferrin binding protein [27] . It is possible that multiple mechanisms, such as acidi¢cation and accumulation of chelating agents as a result of bacterial metabolism promote iron liberation from transferrin in the presence of high bacterial densities [22, 27] . The number of invading bacteria evidently plays a role in the pathogenesis of septic infections. S. epidermidis often contaminates central venous catheters, where bio¢lm formation promotes the adherence and protection of the bacteria [28] . In stem cell transplant patients, the oral mucosa is another possible route of infection due to treatment-related mucositis [29] . In catheter infections, there is an association between the number of organisms retrieved from the catheter surface and the risk of infection, and infection occurs only when the number exceeds a certain quantitative threshold [30, 31] . In a study of catheterrelated bacteraemias, blood drawn from the catheters had up to 10 5 cfu ml 31 of coagulase-negative staphylococci, whereas peripheral blood samples had 10 1^1 0 2 cfu ml 31 [32] . Another study showed that the mean bacterial cell concentration in peripheral blood samples in blood stream infections caused by coagulase-negative staphylococci was 33 cfu ml 31 [33] . It may be reasoned that a high local density of S. epidermidis in the intravenous catheters promotes bacterial growth also in the absence of NTBI, whereas the proliferation of low counts occurring in the peripheral blood may depend on the availability of NTBI.
In the present study, apotransferrin administration to the patients e¡ectively bound NTBI and restored the growth-inhibitory e¡ect of patient serum against S. epidermidis. Repeated higher doses of apotransferrin maintained the growth-inhibitory e¡ect in the serum of ¢ve out of the eight patients during the whole stem cell transplantation period. Earlier studies have described the reduced ability of serum from leukaemia patients to prevent growth of Pseudomonas aeruginosa [34] , Escherichia coli, S. aureus [35] and Candida albicans [15] . Several studies have also shown that transferrin displays a growth-inhibitory e¡ect in vitro on opportunistic organisms, such as Vibrio vulni¢cus [36] , Rhizopus [37] , C. albicans [15, 38] and Histoplasma capsulatum [39] . Recently, an anticryptococcal protein in serum was identi¢ed as apotransferrin [40] . Thus, apotransferrin administration could have an impact on infections caused by several bacteria or fungi.
Among the small number of patients in the present study, the incidence of septic infections was not signi¢-cantly di¡erent in the patients who received apotransferrin than in the control patients. When the patient groups were compared with respect to the total number of days with fever or elevated CRP, the patients who received repeated doses of apotransferrin had signi¢cantly fewer positive days than the patients who did not receive apotransferrin. Correspondingly, the number of days with intravenous antibiotics was signi¢cantly smaller during the study period in the patients who received repeated apotransferrin infusions. Although the patients were not compared in a randomised setting, this may suggest that repeated infusions of apotransferrin could protect the neutropenic patients against septic infections.
In conclusion, our results suggest a major pathogenic role for NTBI in septic S. epidermidis infections in neutropenic patients. With increasing resistance of microbes to antibiotics, binding of NTBI with apotransferrin could o¡er a method to enhance physiological resistance against infections. However, the clinical e⁄cacy of this therapeutic concept remains to be investigated in prospective controlled trials. NTBI was measured by the bleomycin assay. Data are number of positive days/total days (%) during the study period from 6 days before stem cell transplantation to 14 days after it. P values were calculated by the Fisher's exact test. *P 6 0.05, **P 6 0.01 vs. no apotransferrin dose. a CRP was measured on an average of 14 of the total 21 days, mainly after the stem cell transplantation.
